Counseling Points Multiple Sclerosis - Spring 2015 - 2

FACULTY:
Series Editor
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center
Maywood, IL

Counseling Points™
Encouraging Monitoring and Follow-up
in MS Care

Faculty Panel
Beverly A. Layton RN, CCRC, MSCN
Multiple Sclerosis Nurse Consultant
Birmingham, AL

Continuing Education Information

Marie Moore, FNP
Nurse Practitioner
CMC-Multiple Sclerosis Center
Charlotte, NC

This educational activity is designed to meet the needs of nurses who treat or who
have an interest in patients with multiple sclerosis (MS).

Valerie Stickel-Diehl, RN, MS, MSCN
Nurse Case Manager
Mercy Ruan Neuroscience Center
Des Moines, IA

To provide nurses who treat patients with MS with information and practice advice
related to safety monitoring and follow-up associated with MS disease-modifying
therapies.

Faculty Disclosure Statements
Amy Perrin Ross has received honoraria for
participating on the Speakers' Bureaus for
Acorda, Bayer HealthCare, Inc., Biogen Idec,
EMD Serono, Genzyme, Mallinckrodt, Novartis,
Pfizer, and Teva Pharmaceuticals, and as a
consultant for Acorda, Bayer HealthCare, Inc.,
EMD Serono, Genzyme, Mallinckrodt, Novartis,
and Teva Pharmaceuticals.
Marie Moore has received honoraria for
participating on the Speakers' Bureaus for
Biogen Idec, Genzyme, Novartis, and Pfizer.
Beverly Layton has received honoraria for
participating on the Speaker's Bureaus for
Biogen Idec, Genzyme, and Pfizer; consulting for
Bayer, Genzyme, Novartis, and Questcor; and
from Biogen Idec for research support.
Valerie Stickel-Diehl has received honoraria
for participating on the Speakers' Bureaus for
Acorda Therapeutics, Biogen Idec, Genzyme,
Novartis, and Pfizer.
Planners and Managers
The following planners and managers have
declared no relevant financial relationships:
Joseph J. D'Onofrio, Frank Marino, Katherine
Wandersee.

PUBLISHING INFORMATION:
Publishers
Joseph J. D'Onofrio
Frank M. Marino
Delaware Media Group
66 South Maple Avenue
Ridgewood, NJ 07450
Tel: 201-612-7676
Fax: 201-612-8282
Websites: www.delmedgroup.com
www.counselingpoints.com
Medical Writer
Katherine Wandersee
Art Director
James Ticchio
Cover photo credits: © StockPhotosArt.com / Veer; Thomas
Pajot / Veer; PicsFive / Veer; cienpies / Veer; Alloy Photography
/ Veer
Copyright © 2015, Delaware Media Group, Inc. All rights
reserved. None of the contents may be reproduced in any
form without prior written permission from the publisher. The
opinions expressed in this publication are those of the faculty
and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or Teva
Pharmaceuticals.

www.counselingpoints.com

Target Audience

Purpose

Learning Objectives
Upon completion of this educational activity, the participant should be able to:
* Discuss current challenges associated with pre-treatment monitoring for MS disease-modifying therapies (DMTs)
* Assess methods for recommending and encouraging regular follow-up while on MS
DMT
* Review how appropriate monitoring can prevent complications of MS DMTs

Continuing Education Credit
This continuing nursing education activity is developed under the joint providership
of Delaware Media Group and NP Alternatives.
NP Alternatives is accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center's Commission on Accreditation.
Laurie Scudder, DNP, NP, served as nurse planner and reviewer for this activity. She
has declared no relevant financial relationships.
This activity has been awarded 1.0 contact hours (1.0 contact hours are in the area of
pharmacology). Code: MSCP04015.
In order to earn credit, please read the entire activity and complete the post-test and
evaluation at the end. Approximate time to complete this activity is 60 minutes.
This program expires April 1, 2017.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses
of agents that are not approved by the FDA. Teva Pharmaceuticals and Delaware Media
Group do not recommend the use of any agent outside of the labeled indications. The
opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Teva Pharmaceuticals and Delaware Media Group.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management.
Any medications, diagnostic procedures, or treatments discussed in this publication
should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.
2

Counseling Points Multiple Sclerosis - Spring 2015

Table of Contents for the Digital Edition of Counseling Points Multiple Sclerosis - Spring 2015